Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 21-year-old experiencing itchy and burning scalp with hair loss was diagnosed with MPB and scalp inflammation. They were prescribed Ketoconazole, Prednisone, Clindamycin, and Finasteride, and are considering trying antihistamines, dietary changes, and "nopoo" to alleviate symptoms.

Topical melatonin shows promise for increasing hair density with minimal side effects. The user is transitioning from oral finasteride to a compounded minoxidil and finasteride solution and considering melatonin and bimatoprost as additional treatments.

Rogaine prices in Canada are unlikely to increase due to tariffs, and generic minoxidil is recommended as a cheaper alternative. Users suggest buying generic versions from places like Costco or using a minoxidil/finasteride combo cream for cost savings.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Some users maintained hair gains after stopping microneedling while continuing minoxidil and finasteride, while others saw no improvement or experienced hair breakage. One user switched to oral minoxidil and continued finasteride and dutasteride after seeing no results from microneedling.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The conversation discusses using finasteride, dutasteride, minoxidil, cialis, and metformin to protect hair and health. Some users caution against self-prescribing these drugs due to potential risks and complications.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

A 23-year-old male is using topical Minoxidil 5% and Finasteride 0.1% for hair maintenance and is considering switching to oral Finasteride. He also takes Vitamin D, K2, and a multivitamin, and seeks advice on whether to change his treatment.

The user has been using finasteride, minoxidil, and derma stamping for hair loss but is considering switching to dutasteride due to lack of improvement. They are seeking advice on obtaining dutasteride, which is off-label in Denmark, and are considering ordering it online if not prescribed.

A user switched from finasteride to dutasteride, taking dutasteride twice weekly and considering continuing finasteride on other days. Some users shared their experiences with similar switches, noting that dutasteride lowers DHT more effectively and advising against taking both simultaneously.

A user plans a drug-free hair transplant while waiting for future treatments like stem cell therapies, which are projected to be available between 2028 and 2030. Many users express skepticism about the availability of new treatments, suggesting that relying on them is risky and that finasteride remains the most effective option.

Pyrilutamide's inconsistent trial results, with phase II showing positive hair growth and phase III failing to show significant gains, possibly due to COVID-related disruptions. Users discuss modest results from kx-826 treatment.

A user shared their 5-month progress using 0.5mg oral Dutasteride daily, topical Minoxidil twice a day, and weekly micro-needling for hair loss, after experiencing side effects with Finasteride. They reported no side effects with Dutasteride and noted improvement in their hair condition.

The conversation is about disappointment in the lack of new hair loss cures, with discussions on treatments like finasteride, minoxidil, and hair transplants. Some users express hope for future advancements, while others debate the effectiveness and side effects of current treatments.

The user tried various hair loss treatments, including finasteride, minoxidil, dutasteride, and a hair transplant, but experienced continued hair thinning. Stress, genetics, and past medication use are considered possible factors.

A user shared their 13-month follow-up results after a hair transplant using Hybrid FUE+DHI techniques in Istanbul, Turkey. Opinions on the results were mixed, with some praising the natural look and others criticizing the hairline and suggesting it was an advertisement.

The user has been using finasteride and dutasteride for hair loss, along with minoxidil and ketoconazole shampoo, due to early onset male pattern baldness and family history. They switched from finasteride to dutasteride after two months and have been using a dermaroller weekly.

RU58841 shows the strongest results despite weaker binding affinity, while KX-826 and CB-03-01 are more expensive and have minimal side effects. RU58841 is considered effective but has potential health risks if ingested; users report positive outcomes with RU58841 and finasteride.

Oral minoxidil can cause rare facial bloating, especially at higher doses and in women. Reducing sodium intake, drinking more water, and adjusting the dose can help manage side effects.

A user shared their experience with two hair transplants in Istanbul, highlighting the importance of choosing clinics with a low doctor-to-patient ratio, ISHRS membership, thorough consultations, and reliable aftercare. They emphasized the significance of PRP shots post-procedure and advised careful selection of clinics, especially for crown procedures, due to limited donor area opportunities.

The user experienced severe side effects from finasteride, including hormonal imbalances and cognitive issues, leading to a recommendation to stop its use. They plan to follow up with tests to rule out a pituitary tumor and are considering topical treatments as alternatives.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

Finasteride helps with hair loss by lowering DHT levels in the scalp, which is more important than blood DHT levels. If finasteride is not effective, consulting a doctor or considering switching to dutasteride may be advisable.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

Various peptides are discussed for treating male pattern baldness, with some available for topical use like GHK-Cu and Ac-KGHK, while others remain in research stages. Users are interested in experiences and sourcing these treatments.